Anti-Integrin aVb3 [23C6]
Invented at Queen Mary University of London
- Datasheet
- References (10)
- Inventor Info
Info
![Image thumbnail for Anti-Integrin aVb3 [23C6]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/52e973f5-f992-4195-b252-e47bfedb5c9f.jpg)
| Catalogue Number | 151039 |
| Applications | FACS IHC IP Fn |
| Antigen/Gene or Protein Targets | Integrin alpha V ß3 (CD51/61; Osteoclast Functional Antigen) |
| Reactivity | Human |
| Relevance | Integrins are heterodimeric cell surface receptors composed of alpha and beta subunits, which mediate cell-cell and cell-extracellular matrix attachments. Aberrant integrin expression has been found in many epithelial tumours. Changes in integrin expression have been shown to be important for the growth and early metastatic capacity of melanoma cells. Integrin alpha V associates with integrin beta3 to form the osteoclast functional antigen (vitronectin receptor). Integrin alpha V is found in osteoclasts, placenta, melanoma cell lines and some epithelial cell lines. Expression of integrin alpha V increases with melanoma progression. 23C6 may be useful for bone resorption modulation, osteoclast identification, receptor purification, malignant melanoma identification and treatment. |
| Host | Mouse |
| Immunogen | A cell suspension containing osteoclasts from osteoclastomas. |
| Positive Control | Tonsil |
| Subclass | IgG1 |
| Molecular Weight (kDa) | 125/124, 150 |
| Myeloma Used | P3X63Ag8.653 |
| Recommended Growing Conditions | DMEM + 5% FCS |
| Strain | Balb/c |
| Notes | 125/124 kDa (reduced), 150kDa (non-reduced) |
| Research Area | Adhesion, Cancer, Cardiovascular |
References: 10 entries
MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells.
Europe PMC ID: 20027628
Chetty et al. 2010. Int J Cancer. 127(5):1081-95. PMID: 20027628.
IP
Martino et al. 2009. Biomaterials. 30(6):1089-97. PMID: 19027948.
Controlling integrin specificity and stem cell differentiation in 2D and 3D environments through regulation of fibronectin domain stability.
Europe PMC ID: 19027948
Zhou et al. 2006. J Exp Med. 203(4):1067-80. PMID: 16606672.
Regulation of osteoclast function and bone mass by RAGE.
Europe PMC ID: 16606672
Marshall et al. 1995. J Cell Sci. 108 ( Pt 3):1227-38. PMID: 7542669.
Alpha v beta 1 is a receptor for vitronectin and fibrinogen, and acts with alpha 5 beta 1 to mediate spreading on fibronectin.
Europe PMC ID: 7542669
Horton et al. 1985. Cancer Res. 45(11 Pt 2):5663-9. PMID: 4053038.
Monoclonal antibodies to osteoclastomas (giant cell bone tumors): definition of osteoclast-specific cellular antigens.
Europe PMC ID: 4053038
Add a reference
References: 10 entries
MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells.
Chetty et al. 2010. Int J Cancer. 127(5):1081-95. PMID: 20027628.
IP
Martino et al. 2009. Biomaterials. 30(6):1089-97. PMID: 19027948.
Controlling integrin specificity and stem cell differentiation in 2D and 3D environments through regulation of fibronectin domain stability.
Zhou et al. 2006. J Exp Med. 203(4):1067-80. PMID: 16606672.
Regulation of osteoclast function and bone mass by RAGE.
Marshall et al. 1995. J Cell Sci. 108 ( Pt 3):1227-38. PMID: 7542669.
Alpha v beta 1 is a receptor for vitronectin and fibrinogen, and acts with alpha 5 beta 1 to mediate spreading on fibronectin.
Horton et al. 1985. Cancer Res. 45(11 Pt 2):5663-9. PMID: 4053038.
Monoclonal antibodies to osteoclastomas (giant cell bone tumors): definition of osteoclast-specific cellular antigens.
Add a reference
